Veria Vacchiano

List of Publications by Year
in descending order

40 papers	603 citations	840776 11 h-index	642732 23 g-index
40 all docs	40 docs citations	40 times ranked	982 citing authors

#	Article	IF	Citations
1	Quality of life assessment in adult spinal muscular atrophy patients treated with nusinersen. Journal of Neurology, 2022, 269, 3264-3275.	3.6	6
2	Epidemiological, Clinical and Genetic Features of ALS in the Last Decade: A Prospective Population-Based Study in the Emilia Romagna Region of Italy. Biomedicines, 2022, 10, 819.	3.2	10
3	The Effect of Curcumin on Idiopathic Parkinson Disease: A Clinical and Skin Biopsy Study. Journal of Neuropathology and Experimental Neurology, 2022, 81, 545-552.	1.7	11
4	Brain metabolic correlates of apathy in amyotrophic lateral sclerosis: An 18F–FDG–positron emission tomography stud. European Journal of Neurology, 2021, 28, 745-753.	3.3	10
5	Targeted sequencing panels in Italian ALS patients support different etiologies in the ALS/FTD continuum. Journal of Neurology, 2021, 268, 3766-3776.	3.6	12
6	Needle electromyography of craniobulbar muscles in patients with amyotrophic lateral sclerosis: Direct comparison between genioglossus and masseter muscles. Clinical Neurophysiology, 2021, 132, 744-745.	1.5	2
7	In Vivo Diagnosis of Synucleinopathies. Neurology, 2021, 96, e2513-e2524.	1.1	63
8	Neurological involvement in Ile68Leu (p.Ile88Leu) ATTR amyloidosis: not only a cardiogenic mutation. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 173-181.	3.0	5
9	The clinical spectrum of multisystem proteinopathy: Data from a neurodegenerative cohort. Journal of the Neurological Sciences, 2021, 426, 117478.	0.6	3
10	Antibodies to neuronal surface antigens in patients with a clinical diagnosis of neurodegenerative disorder. Brain, Behavior, and Immunity, 2021, 96, 106-112.	4.1	16
11	The m.3890G>A/MT-ND1 mtDNA rare pathogenic variant: Expanding clinical and MRI phenotypes. Mitochondrion, 2021, 60, 142-149.	3.4	4
12	Prognostic value of EMG genioglossus involvement in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2021, 132, 2416-2421.	1.5	3
13	6MWT as measure of motor function and endurance in SMA type 3 patients treated with nusinersen. Journal of the Neurological Sciences, 2021, 429, 119385.	0.6	0
14	Plasma and CSF Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: A Cross-Sectional and Longitudinal Study. Frontiers in Aging Neuroscience, 2021, 13, 753242.	3.4	33
15	Efficacy and safety of rituximab therapy in patients with autoimmune neurological disorders. Journal of the Neurological Sciences, 2021, 429, 118822.	0.6	0
16	Pyramidal pathway changes at conventional brain 3–T-MRI in patients with hereditary spastic paraplegia. Journal of the Neurological Sciences, 2021, 429, 118259.	0.6	0
17	A sight into the elderly ALS patients in Emilia Romagna region: Epidemiological and clinical features of late onset ALS in a prospective population-based study. Journal of the Neurological Sciences, 2021, 429, 119390.	0.6	0
18	CSF Heavy Neurofilament May Discriminate and Predict Motor Neuron Diseases with Upper Motor Neuron Involvement. Biomedicines, 2021, 9, 1623.	3.2	4

#	Article	IF	Citations
19	Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1166-1174.	1.9	99
20	Diagnostic and Prognostic Value of Conventional Brain MRI in the Clinical Work-Up of Patients with Amyotrophic Lateral Sclerosis. Journal of Clinical Medicine, 2020, 9, 2538.	2.4	14
21	Movement Disorders Associated with GABA A Receptor Encephalitis: A Video Case Report. Movement Disorders Clinical Practice, 2020, 7, 681-683.	1.5	3
22	Denervation findings on EMG in amyotrophic lateral sclerosis and correlation with prognostic milestones: Data from a retrospective study. Clinical Neurophysiology, 2020, 131, 2017-2022.	1.5	6
23	Early neurological manifestations of hospitalized COVID-19 patients. Neurological Sciences, 2020, 41, 2029-2031.	1.9	72
24	Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis. Journal of Neurology, 2020, 267, 1699-1708.	3.6	39
25	Exacerbation of myasthenia gravis after amoxicillin therapy: a case series. Neurological Sciences, 2020, 41, 2255-2257.	1.9	6
26	Combined brain positron emission tomography/magnetic resonance imaging in GABA A receptor encephalitis. European Journal of Neurology, 2019, 26, e88-e89.	3.3	7
27	Subcutaneous immunoglobulin treatment and leucopenia in acquired demyelinating peripheral neuropathies. European Journal of Neurology, 2019, 26, e80-e81.	3.3	1
28	Clinical Reasoning: A 58-year-old man with distal hand weakness. Neurology, 2019, 92, e1395-e1400.	1.1	4
29	Broadening the Spectrum of Adulthood X-Linked Adrenoleukodystrophy: A Report of Two Atypical Cases. Frontiers in Neurology, 2019, 10, 70.	2.4	5
30	Functional MRI study in a case of Charles Bonnet syndrome related to LHON. BMC Neurology, 2019, 19, 350.	1.8	12
31	The autonomic innervation of hairy skin in humans: an in vivo confocal study. Scientific Reports, 2019, 9, 16982.	3.3	28
32	Subcutaneous immunoglobulin treatment and thromboembolic risk. Annals of Allergy, Asthma and Immunology, 2018, 120, 433-435.	1.0	3
33	Arthritic psoriasis during natalizumab treatment: a case report and review of the literature. Neurological Sciences, 2018, 39, 181-183.	1.9	8
34	First-line disease-modifying drugs in relapsing–remitting multiple sclerosis: an Italian real-life multicenter study on persistence. Current Medical Research and Opinion, 2018, 34, 1803-1807.	1.9	13
35	Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship. Clinical Neuropharmacology, 2018, 41, 171-176.	0.7	10
36	Teeth loss after teriflunomide treatment: Casual or causal? A short case series. Multiple Sclerosis and Related Disorders, 2018, 24, 120-122.	2.0	5

#	Article	IF	Citations
37	Lesion Load May Predict Long-Term Cognitive Dysfunction in Multiple Sclerosis Patients. PLoS ONE, 2015, 10, e0120754.	2.5	31
38	Uric acid: a potential biomarker of multiple sclerosis and of its disability. Clinical Chemistry and Laboratory Medicine, 2015, 53, 753-9.	2.3	38
39	Vitamin K cream reduces reactions at the injection site in patients with relapsing–remitting multiple sclerosis treated with subcutaneous interferon beta – VIKING study. Multiple Sclerosis Journal, 2015, 21, 1215-1216.	3.0	6
40	JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level. Therapeutics and Clinical Risk Management, 2014, 10, 807.	2.0	11